Imagine this: Your doctor prescribes a medicine that finally controls your chronic condition. A drug company offers a copay card to help cover your share—maybe knocking your monthly cost down to $5 or $0. Sounds great, right? But then your insurance plan pulls a switch: They say that help doesn't count toward your deductible or your yearly out-of-pocket maximum. Suddenly, you're on the hook for thousands once the card runs out—or even sooner.

This isn't a rare horror story. It's happening through programs called copay accumulators and copay maximizers, and it's hitting patients hard—especially those on expensive specialty drugs for conditions like rheumatoid arthritis, cancer, HIV, hepatitis, Crohn's, or cystic fibrosis.

What Are These Programs, and How Do They Hurt Patients?

• Copay Accumulators: The insurance company takes the drug company's copay help and applies it to your prescription fill—but it doesn't count toward your deductible or annual out-of-pocket limit. You still pay full price after the card is used up, even if you've "spent" thousands via the card. Result? You hit sky-high costs faster, skip doses, or stop treatment altogether.
• Copay Maximizers: These go further. The plan sets your copay to match the max help from the drug company (say, $5,000–$15,000 a year), spreads it out monthly, and pockets most of the savings. Again, none of it counts toward your deductible or max. The plan saves money; you face unpredictable bills and risk losing access to the med that works for you.

These tricks let insurers capture money meant to help you, not them. Patients end up rationing meds, facing disease flares, or switching to less effective treatments—all while the insurance company benefits.

The Federal Rule You're Hearing About: NBPP (Notice of Benefit and Payment Parameters)

The NBPP is basically the government's annual "rulebook update" for Affordable Care Act (ACA) plans—like the individual and small-group markets on HealthCare.gov. It sets rules for what plans must cover, how much you pay out-of-pocket, and other protections.

In recent years:

• The 2025 NBPP said all prescription drugs covered by a plan (beyond a state's basic list) count as "essential health benefits" (EHBs). That means ACA rules cap your annual out-of-pocket costs for them.
• But this only applied to individual and small-group plans—not big employer-sponsored or self-insured plans (which cover most working Americans).

A court case (HIV and Hepatitis Policy Institute v. HHS) struck down an older rule that let plans ignore most manufacturer help for cost-sharing. The court said: For most drugs (especially without a generic option), that help should count toward your deductible and out-of-pocket max. But enforcement has been on hold.

The 2026 Proposed Rule: What It Says (and Doesn't Say)

In October 2024, CMS (with HHS, Treasury, and Labor—the "Tri-agencies") released the NBPP for 2026 proposed rule. It didn't fix the big problems right away. Instead, it promised two future rule makings:

1. One to extend EHB protections to employer-sponsored and self-insured plans—so all prescription drugs get the same cost-sharing caps, no matter your job.
2. Another to finally decide if drug manufacturer assistance counts as "cost-sharing" under the ACA—addressing accumulators and maximizers head-on, based on the court ruling.

Until those future rules drop, plans can keep using accumulators and maximizers. That means continued risk of surprise high costs, skipped meds, and worse health outcomes for patients who rely on manufacturer help.

These delays highlight how policy moves slowly while patients face real hardship every month.

Why Patients Should Care—and What You Can Do

If you have employer coverage or use a specialty med with copay help, these programs could hit your wallet hard. They make "affordable" coverage feel anything but affordable. This is especially true when combined with other barriers like shifting costs or insurance denials (as our partners at the Patient Inclusion Council have shown in recent surveys).

Here's how to protect yourself:

• Check your plan documents or call your insurer: Ask if they use accumulators, maximizers, or "copay adjustment programs."
• Talk to your doctor or pharmacist about alternatives or patient assistance programs.
• Track your state laws—over 20 states (plus D.C. and Puerto Rico) have banned or limited accumulators for state-regulated plans.
• Stay informed: Follow Patients Rising and groups like HIV+Hepatitis Policy Institute for updates on the upcoming rules. 

True affordability means predictable costs and access to the meds that work for your body—not games that benefit insurers. We'll keep advocating so patient voices drive the fixes.

Have you run into accumulators or maximizers? Hit the share your story button and tell us all about it!